← Back to headlines
Akari Therapeutics Adjusts ADS Ratio for Nasdaq Compliance
Akari Therapeutics has revised its American Depositary Share (ADS) ratio as a strategic move to ensure continued compliance with Nasdaq listing requirements.
17 Mar, 20:41 — 17 Mar, 20:41
Sources
Showing 1 of 1 sources
